1. Bergengren O, Garmo H, Bratt O, et al, Determinants for choosing and adhering to active surveillance for localised prostate cancer: a nationwide population-based study, BMJ Open 2019; 9:e033944. Komplett artikel. 
    2. Gincy George , Hans Garmo , Sarah Rudman, Lars Holmberg, David Robinson, Pär Stattin, Jan Adolfsson and Mieke Van Hemelrijck. Long-term adherence to GnRH agonists in men with prostate cancer. A nation-wide population-based study in prostate cancer data base Sweden. Scandinavian Journal of Urology 2019, Dec 16:1-7.
    3. Godtman RA, Månsson M, Bratt O, Robinsson D, Johansson E, Stattin P, Kjölhede H. Development and validation of a prediction model for identifying men with intermediate- or high-risk prostate cancer for whom bone imaging is unnecessary: a nation-wide population-based study. Scand J Urol. 2019 Dec 5:1-7
    4. Zelic R, Zugna D, Garmo H, Stattin P, Richiardi L, Akre O, Pettersson A. Predicting prostate cancer death with different pre-treatment risk-stratification tools: a head-to-head comparison in a nationwide cohort study. Eur Urol 2019 Oct 9. Sammanfattning
    5. Loeb S, Cazzaniga W, Robinson D, Garmo H, Stattin P. Opioid Use After Radical Prostatectomy: Nationwide, Population-Based Study in Sweden.  J Urol. 2019  Jul 17:101097. Sammanfattning
    6. Westerberg M, Franck Lissbrant I, Damber JE, Robinson D, Garmo H, Stattin P. Temporal changes in survival in men with de novo metastatic prostate cancer: nationwide population-based study. Act Oncol. 2019 Sep 17:1-6. Sammanfattning .
    7. Stranne J, Axen E, Franck-Lissbrant I, Fransson P, Frånlund M, Hugosson J, Khatami A, Koss-Modig K, Lodding P, Nyberg M, Stattin P, Bratt O. Single institution followed by national implementation of systematic surgical quality control and feedback for radical prostatectomy: a 20-year journey. World J Urol. 2019 Aug 6. Sammanfattning.
    8. Cazzaniga W, Godtman RA, Carlsson S, Ahlgren G, Johansson E, Robinson D, Hugosson J, Stattin P. Population-based, nationwide registration of prostatectomies in Sweden. J Surg Oncol. 2019 Sep;120(4):803-812. Sammanfattning
    9. Robinson D, Garmo H, Van Hemelrijck M, Damber JE, Bratt O, Holmberg L, Wahlund LO, Stattin P, Adolfsson J. Androgen deprivation therapy for prostate cancer and risk of dementia. BJU Int. 2019 Jul;124(1):87-92. SammanfattningKomplett artikel
    10. Beckmann K, Russell B, Josephs D, Garmo H, Haggstrom C, Holmberg L, Stattin P, Van Hemelrijck M, Adolfsson J. Chronic inflammatory diseases, anti-inflammatory medications and risk of prostate cancer: a population-based case-control study. BMC Cancer. 2019 Jun 21;19(1):612. Sammanfattning
    11. Zelic R, Zugna D, Bottai M, Andrén O, Fridfeldt J, Carlsson J, Davidsson S, Fiano V, Fiorentino M, Giunchi F, Grasso C, Lianas L, Mascia C, Molinaro L, Zanetti G, Richiardi L, Pettersson A, Akre O. Estimation of Relative and Absolute Risks in a Competing-Risks Setting Using a Nested Case-Control Study Design: Example From the ProMort Study. Am J Epidemiol. 2019 Jun 1;188(6):1165-1173. Sammanfattning
    12. Ventimiglia E, Van Hemelrijck M, Lindhagen L Stattin P, Garmo H. How to measure temporal changes in care pathways for chronic diseases using health care registry data. BMC Med Inform Decis Mak. 2019 May 30;19(1):103. SammanfattningKomplett artikel
    13. Cazzaniga W, Garmo H, Robinson D, Holmberg L, Bill-Axelson A, Stattin P. Mortality after radical prostatectomy in a matched contemporary cohort in Sweden compared to the Scandinavian Prostate Cancer Grup 4 (SPCG-4) study. BJU Int. 2019 Mar;123(3):421-428. Sammanfattning
    14. Sverrisson I, Folkvaljon F, Chabok A, Stattin P, Smedh K, Nikberg M. Anastomotic leakage after anterior resection in patients with rectal cancer previously irradiated for prostate cancer.  Eur J Surg Oncol. 2019 Mar;45(3):341-346. Sammanfattning 
    15. Cazzaniga W, Ventimiglia E, Alfano M, Robinson D, Lissbrant IF, Carlsson S, Styrke J, Montorsi F, Salonia A, Stattin P. Mini Review on the Use of Clinical Cancer Registers for Prostate Cancer: The National Prostate Cancer Register (NPCR) of Sweden. Front Med 2019 Mar 22;6:51.. Sammanfattning. Komplett artikel
    16. Arthur R, Møller H, Garmo H, Häggström C, Holmberg L, Stattin P, Malmström H, Lambe M, Hammar N, Walldius G, Robinson D, Jungner I, Van Hemelrijck M. Serum glucose, triglycerides, and cholesterol in relation to prostate cancer death in the Swedish AMORIS study. Cancer Causes Control. 2019 Feb;30(2):195-206. Sammanfattning
    17. Loeb S, Folkvaljon Y, Bratt O, Robinson D, Stattin P. Defining Intermediate-Risk Prostate Cancer Suitable for Active Surveillance. J Urol. 2019 Feb;201(2):292-299. Sammanfattning
    18. Thomsen FB, Bosco C, Garmo H, Adolfsson J, Hammar N, Stattin P, Van Hemelrijck M. Anti-androgen monotherapy versus gonadotropin-releasing hormone agonists in men with advanced, non-metastatic prostate cancer: a register-based, observational study.  Acta Oncol. 2019 Jan;58(1):110-118. Sammanfattning